First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 1×

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdiş, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 1,007

The T cell immune response against SARS-CoV-2

Moss, P. A. H. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,243

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.001 · Cited by 499

COVID-19 vaccine development: milestones, lessons and prospects

Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 478

SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19

Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., & Sette, A. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.010 · Cited by 314

The germinal centre B cell response to SARS-CoV-2

Laidlaw, B. J., & Ellebedy, A. H. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00657-1 · Cited by 268

SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells

Minervina, A. A., Pogorelyy, M. V., Kirk, A. M., Crawford, J. C., Allen, E. K., Chou, C., Mettelman, R. C., Allison, K., Lin, C.-Y., Brice, D. C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01184-4 · Cited by 221

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study

Angyal, A., Longet, S., Moore, S. C., Payne, R., Harding, A. C., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00275-5 · Cited by 182

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Schmidt, T., Klemis, V., Schub, D., Schneitler, S., Reichert, M., Wilkens, H., Sester, U., Sester, M., & Mihm, J. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16818 · Cited by 151

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

Luxi, N., Giovanazzi, A., Capuano, A., Crisafulli, S., Cutroneo, P. M., Fantini, M. P., Ferrajolo, C., Moretti, U., Poluzzi, E., Raschi, E., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01131-6 · Cited by 142

Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study

Madelon, N., Lauper, K., Bréville, G., Royo, I. S., Goldstein, R., Andrey, D. O., Grifoni, A., Sette, A., Kaiser, L., Siegrist, C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab954 · Cited by 136

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19

Hammerman, A., Sergienko, R., Friger, M., Beckenstein, T., Peretz, A., Netzer, D., Yaron, S., & Arbel, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119497 · Cited by 126

One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19

Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., & Rescigno, M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149154 · Cited by 105

A cell-type-specific atlas of the inner ear transcriptional response to acoustic trauma

Milon, B. C., Shulman, E. D., So, K. S., Cederroth, C. R., Lipford, E. L., Sperber, M., Sellon, J. B., Sarlus, H., Pregernig, G., Shuster, B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109758 · Cited by 115

SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine

Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8590 · Cited by 115

High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines

Pape, K. A., Dileepan, T., Kabage, A. J., Kozysa, D., Batres, R., Evert, C., Matson, M., Lopez, S., Krueger, P. D., Graiziger, C. T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109823 · Cited by 103

B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity

Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 101

Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination

Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz‐Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021) · Cells · doi:10.3390/cells10081952 · Cited by 85

NMR Metabolomics Methods for Investigating Disease

Gowda, G. A. N., & Raftery, D. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04606 · Cited by 80

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19

Zollner, A., Watschinger, C., Rössler, A., Farcet, M. R., Penner, A., Böhm, V., Zollner-Kiechl, S., Stampfel, G., Hintenberger, R., Tilg, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103539 · Cited by 75

Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers

Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 74

Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies

Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64

Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion

Mazzoni, A., Salvati, L., Maggi, L., Annunziato, F., & Cosmi, L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101508 · Cited by 69

Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination

Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 60

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Bellusci, L., Grubbs, G., Zahra, F. T., Forgacs, D., Golding, H., Ross, T. M., & Khurana, S. (2022) · Nature Communications · doi:10.1038/s41467-022-32298-w · Cited by 56

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of ConcernPreprint

Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.23.457229 · Cited by 59

Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients

Haskin, O., Ashkenazi‐Hoffnung, L., Ziv, N., Borovitz, Y., Dagan, A., Levi, S. S., Koren, G., Hamdani, G., Erez, D. L., Landau, D., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003922 · Cited by 52

SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people

Narowski, T. M., Raphel, K., Adams, L. E., Huang, J., Vielot, N. A., Jadi, R., de Silva, A. M., Baric, R. S., Lafleur, J., & Premkumar, L. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110336 · Cited by 53

Dynamics of antibody response to CoronaVac vaccine

Fonseca, M. H. G., de Souza, T. D. F. G., Araújo, F. M. D. C., & de Andrade, L. O. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27604 · Cited by 52

The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection

Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48

T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease

Reuken, P. A., Andreas, N., Grunert, P., Glöckner, S., Kamradt, T., & Stallmach, A. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab147 · Cited by 44

SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron

Mazzoni, A., Vanni, A., Spinicci, M., Capone, M., Lamacchia, G., Salvati, L., Coppi, M., Antonelli, A., Carnasciali, A., Farahvachi, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801431 · Cited by 44

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

Fabricius, D., Ludwig, C., Scholz, J. A. M., Rode, I., Tsamadou, C., Jacobsen, E., Winkelmann, M., Grempels, A., Lotfi, R., Janda, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080918 · Cited by 42

Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines

Spinardi, J., & Srivastava, A. K. (2023) · Biomedicines · doi:10.3390/biomedicines11020370 · Cited by 47

Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization

Lamacchia, G., Mazzoni, A., Spinicci, M., Vanni, A., Salvati, L., Peruzzi, B., Bencini, S., Capone, M., Carnasciali, A., Farahvachi, P., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01325-2 · Cited by 43

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y., & Nakazono, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257668 · Cited by 41

Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection

Pieren, D. K. J., Kuguel, S. G., Rosado, J., Robles, A. G., Rey-Cano, J., Mancebo-Pérez, C., Esperalba, J., Falcó, V., Buzón, M. J., & Genescà, M. (2023) · Nature Communications · doi:10.1038/s41467-023-37559-w · Cited by 38

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies

Mazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157990 · Cited by 40

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies

Mazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 36

The intestinal microbiota and improving the efficacy of COVID-19 vaccinations

Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response

Takamatsu, Y., Omata, K., Shimizu, Y., Kinoshita, N., Terada, M., Suzuki, T., Morioka, S., Uemura, Y., Ohmagari, N., Maeda, K., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02716-22 · Cited by 35

Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study

Aikawa, N. E., Kupa, L. D. V. K., Pasoto, S. G., Ribeiro, A. C. D. M., Yuki, E. F. N., Saad, C. G. S., Pedrosa, T. D. N., Fuller, R., Shinjo, S. K., Sampaio-Barros, P. D., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00327-1 · Cited by 28

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Coléon, S., Wiedemann, A., Surénaud, M., Lacabaratz, C., Hüe, S., Prague, M., Cervantes-Gonzalez, M., Wang, Z., Ellis, J., Sansoni, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104062 · Cited by 29

Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History

Tarkowski, M., de Jager, W., Schiuma, M., Covizzi, A., Lai, A., Gabrieli, A., Corbellino, M., Bergna, A., Ventura, C. D., Galli, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793191 · Cited by 28

Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time

Havervall, S., Marking, U. W., Greilert‐Norin, N., Gordon, M., Ng, H., Christ, W., Phillipson, M., Nilsson, P., Hober, S., Blom, K. G., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1388 · Cited by 24

Influencing factors of anti‐SARS‐CoV‐2‐spike‐IgG antibody titers in healthcare workers: A cross‐section study

Reusch, J., Wagenhäuser, I., Gabel, A., Eggestein, A., Höhn, A., Lâm, T., Frey, A., Schubert‐Unkmeir, A., Dölken, L., Frantz, S., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28300 · Cited by 25

Is one vaccine dose enough if you’ve had COVID? What the science says

Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-01609-4 · Cited by 27

Suppressive Monocytes Impair MAIT Cells Response via IL-10 in Patients with Severe COVID-19

Yang, Q., Wen, Y., Qi, F., Gao, X., Chen, W., Xu, G., Wei, C., Wang, H., Tang, X., Lin, J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100228 · Cited by 24

Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies

D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 22

Rapid induction of antigen-specific CD4 + T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccinationPreprint

Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.21.440862 · Cited by 23

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals

Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22

Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex

Tang, J., Grubbs, G., Lee, Y., Huang, C., Ravichandran, S., Forgacs, D., Golding, H., Ross, T. M., & Khurana, S. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103748 · Cited by 20

Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes

Livieratos, A., Gogos, C. A., & Akinosoglou, K. (2024) · Viruses · doi:10.3390/v16050685 · Cited by 23

Serum NMR Profiling Reveals Differential Alterations in the Lipoproteome Induced by Pfizer-BioNTech Vaccine in COVID-19 Recovered Subjects and Naïve Subjects

Ghini, V., Maggi, L., Mazzoni, A., Spinicci, M., Zammarchi, L., Bartoloni, A., Annunziato, F., & Turano, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.839809 · Cited by 19

Tissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*

Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 19

Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection

Wolszczak-Biedrzycka, B., Bieńkowska, A., & Dorf, J. (2021) · Vaccines · doi:10.3390/vaccines9121508 · Cited by 20

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines

Alharbi, N. K., Al‐Tawfiq, J. A., Alwehaibe, A., Alenazi, M. W., Almasoud, A. S., Algaissi, A. A., Alhumaydhi, F. A., Hashem, A. M., Bosaeed, M., & Alsagaby, S. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s362848 · Cited by 18

Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period

Bhattacharya, M., Sharma, A. R., Dhama, K., Agoramoorthy, G., & Chakraborty, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108766 · Cited by 17

SARS-CoV-2-specific T cell and humoral immunity in individuals with and without HIV in an African population: a prospective cohort study

Ngalamika, O., Lidenge, S. J., Mukasine, M. C., Kawimbe, M., Kamanzi, P., Ngowi, J. R., Mwaiselage, J. D., & Tso, F. Y. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.009 · Cited by 16

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Marc, G. P., Álvarez-Paggi, D., & Polack, F. P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150135 · Cited by 15

Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination

Tartaro, D. L., Paolini, A., Mattioli, M., Swatler, J., Neroni, A., Borella, R., Santacroce, E., Nella, A. D., Gozzi, L., Busani, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123724 · Cited by 13

Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study

Li, L., Zheng, C., La, J., Do, N., Monach, P. A., Strymish, J. M., Fillmore, N. R., & Branch‐Elliman, W. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.026 · Cited by 14

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity

Casado, J. L., Häemmerle, J., Vizcarra, P., Rodríguez-Domínguez, M., Velasco, T., Velasco, H., Centenera, E., Romero‐Hernández, B., Fernández-Escribano, M., & Vallejo, A. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1341 · Cited by 13

Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection

Schöfbänker, M., Günther, T., Lorentzen, E. U., Romberg, M.-L., Hennies, M. T., Neddermeyer, R., Müller, M. M., Mellmann, A., Bojarzyn, C. R., Lenz, G., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012624 · Cited by 16

Improved immunologic response to COVID‐19 vaccine with prolonged dosing interval in haemodialysis patients

Haarhaus, M. L., Duhanes, M., Lesevic, N., Matei, B., Ramsauer, B., Rodrigues, R. D. S., Su, J., Haase, M., Santos-Araújo, C., & Macario, F. J. G. R. M. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13152 · Cited by 11

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells

Krause, R. G. E., Moyo-Gwete, T., Richardson, S. I., Makhado, Z., Manamela, N. P., Hermanus, T., Mkhize, N. N., Keeton, R., Benede, N., Mennen, M., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00724-9 · Cited by 9

Non-Markovian modelling highlights the importance of age structure on Covid-19 epidemiological dynamics

Reyné, B., Richard, Q., Selinger, C., Sofonea, M. T., Djidjou‐Demasse, R., & Alizon, S. (2022) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2022008 · Cited by 13

Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants

Xing, M., Wang, Y., Wang, X., Liu, J., Dai, W., Hu, G., He, F., Zhao, Q., Li, Y., Sun, L., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00724-23 · Cited by 12

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

Nantel, S., Bourdin, B., Adams, K., Carbonneau, J., Rabezanahary, H., Hamelin, M., McCormack, D., Savard, P., Longtin, Y., Cheng, M. P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930252 · Cited by 12

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen

Baek, Y. J., Kim, W., Ko, J., Lee, Y.-J., Ahn, J. Y., Kim, J. H., Jang, H. C., Jeong, H. W., Kim, Y. C., Park, Y. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.063 · Cited by 11

Architecture of the SARS-CoV-2-specific T cell repertoire

Zornikova, K. V., Sheetikov, S. A., Rusinov, A. Y., Iskhakov, R. N., & Васильевна, Б. А. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070077 · Cited by 10

CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects

Esparcia-Pinedo, L., Martínez‐Fleta, P., Ropero, N., Vera-Tomé, P., Reyburn, H. T., Casasnovas, J. M., Rodríguez-Frade, J. M., Valés‐Gómez, M., Vilches, C., Martín‐Gayo, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755891 · Cited by 11

SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease

Kelsen, S. G., Braverman, A. S., Aksoy, M. O., Hayman, J. A., Patel, P. S., Rajput, C., Zhao, H., Fisher, S. G., Ruggieri, M. R., & Gentile, N. (2022) · JCI Insight · doi:10.1172/jci.insight.155889 · Cited by 10

Role of IgM Memory B Cells and Spleen Function in COVID-19

Rossi, C. M., Lenti, M. V., Merli, S., & Sabatino, A. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889876 · Cited by 12

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study

Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · mBio · doi:10.1128/mbio.01212-23 · Cited by 11

A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine

Yilmaz, I. C., İpekoğlu, E. M., Saraydar, B., Bildik, T., Aksoy, A. G. B., Evcili, İ., Turay, N., Sürücü, N., Bulbul, A., Guvencli, N., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126787 · Cited by 10

Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital

Costa, C. S., Scozzari, G., Migliore, E., Galassi, C., Ciccone, G., Ricciardelli, G., Scarmozzino, A., Angelone, L., Cassoni, P., Cavallo, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071031 · Cited by 11

Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response

Verma, A., Manojkumar, A., Dhasmana, A., Tripathi, M. K., Jaggi, M., Chauhan, S. C., Chauhan, D. S., & Yallapu, M. M. (2024) · Nanotheranostics · doi:10.7150/ntno.91910 · Cited by 11

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

Salvaggio, M., Fusina, F., Albani, F., Salvaggio, M., Beschi, R., Ferrari, E., Costa, A. C. S., Agnoletti, L., Facchi, E., & Natalini, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184204 · Cited by 10

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants

Vega, M.-A. D. L., Polychronopoulou, E., Ara, X. I. I. I., Ding, Z., Chen, T., Liu, Q., Lan, J., Nepveu-Traversy, M.-É., Fausther‐Bovendo, H., Zaidan, M., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2169198 · Cited by 10

Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity

Silva‐Moraes, V., Souquette, A. H., Sautto, G. A., Paciello, I., Antonelli, G., Andreano, E., Rappuoli, R., Teixeira‐Carvalho, A., & Ross, T. M. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300041 · Cited by 10

Humoral and cellular immunity against diverse SARS-CoV-2 variants

Chen, C., Wang, X., & Zhang, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.10.003 · Cited by 10

Magnitude and Durability of the Antibody Response to mRNA-Based Vaccination Among SARS-CoV-2 Seronegative and Seropositive Health Care Personnel

Ciccone, E. J., Zhu, D., Gunderson, A. K., Hawke, S., Ajeen, R., Lodge, E. K., Shook‐Sa, B. E., Abernathy, H., Garrett, H. E., King, E., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae009 · Cited by 9

Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants

Monge, S., Rojas‐Benedicto, A., Olmedo, C., Martín‐Merino, E., Mazagatos, C., Limia, A., Sierra, M. J., Larrauri, A., Hernán, M. Á., IBERCovid, et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac429 · Cited by 9

Flow cytometry profiling of cellular immune response in COVID-19 infected, recovered and vaccinated individuals

Kumari, D., Singh, S., Kumari, M., Gupta, H., Chauhan, D., Singh, K., Eslavath, M. R., Bhushan, B., Dogra, V., Bargotya, M., et al. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152392 · Cited by 8

Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)

Boongird, S., Setthaudom, C., Kitpermkiat, R., Prasongtanakij, S., Srisala, S., Chuengsaman, P., Nongnuch, A., Assanatham, M., Kiertiburanakul, S., Malathum, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10071064 · Cited by 8

The megakaryocyte: a cell with 3 faces as a mythic god?

Vainchenker, W., & Raslova, H. (2021) · Blood · doi:10.1182/blood.2021012760 · Cited by 5

Study of Naturally-derived Biomolecules as Therapeutics against SARS-CoV-2 Viral Spike Protein

Khanal, P., Chawla, U., Praveen, S., Malik, Z., Malik, S., Yusuf, M., Khan, S. A., & Sharma, M. K. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i28a31524 · Cited by 8

SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis

Limoges, M.-A., Lortie, A., Demontier, É., Quenum, A., Lessard, F., Drouin, Z., Carrier, N., Nguimbus, L. M., Beaulieu, M., Boire, G., et al. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad086 · Cited by 8

Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2

Livieratos, A., Schiro, L. E., Gogos, C. A., & Akinosoglou, K. (2024) · Vaccines · doi:10.3390/vaccines12121444 · Cited by 7

Humoral responses after inactivated COVID‐19 vaccination in individuals with and without prior SARS‐CoV‐2 infection: A prospective cohort study

Jia, M., Wang, X., Gong, W., Zhong, J., Leng, Z., Ren, L., Feng, S., Guo, L., Gao, L., Liang, X., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28055 · Cited by 6

Donor selection for adoptive cell therapy with CD45RA− memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release

Al‐Akioui‐Sanz, K., Pascual-Miguel, B., Díaz‐Almirón, M., Mestre‐Durán, C., Navarro‐Zapata, A., Villa, L. C., Martín-Cortázar, C., Vicario, J. L., Moreno, M. Á., Balas, A., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.12.001 · Cited by 5

The Journal of Clinical Investigation in the time of COVID-19

Casadevall, A., Jackson, S., Semenza, G. L., Tomaselli, G. F., & Ahima, R. S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci156409 · Cited by 6

Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens

Isogawa, M., Onodera, T., Ainai, A., Kotaki, R., Kanno, T., Saito, S., Tobiume, M., Tokunaga, K., Hara, M., Hirota, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00054-x · Cited by 5

Assessment of COVID-19 mRNA vaccination titer and side effects in healthy volunteers

Kozakai, R., Kushida, A., Moumouni, P. F. A. A., Okuma, S., Takahashi, K., Hoshi, K., Sato, Y. A., Takahashi, M., Chida, N., Takahashi, M., et al. (2022) · Journal of Laboratory Medicine · doi:10.1515/labmed-2021-0156 · Cited by 5

Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens

Culebras, E., Martínez, M., Novella, C., León, J. M., Marcos, E., Delgado‐Iribarren, A., & Ríos, E. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1370859 · Cited by 6

Estimated public health impact of concurrent mask mandate and vaccinate-or-test requirement in Illinois, October to December 2021

Castonguay, F. M., Barnes, A., Jeon, S., Fornoff, J., Adhikari, B. B., Fischer, L. S., Greening, B., Hassan, A. O., Kahn, E. B., Kang, G. J., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-18203-8 · Cited by 5

A shot for the US economy

Gächter, M., Huber, F., & Meier, M. (2022) · Finance research letters · doi:10.1016/j.frl.2021.102638 · Cited by 4

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Lozano‐Ojalvo, D., Cámara, C., López‐Granados, E., Nozal, P., Molina, L. D. P., Bravo‐Gallego, L. Y., Paz‐Artal, E., Pion, M., Correa‐Rocha, R., Ortíz, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109570 · Cited by 109

Differential Effects of the Second SARS-CoV-2 mRNA Vaccine Dose on T Cell Immunity in Naïve and COVID-19 Recovered IndividualsPreprint

Lozano‐Ojalvo, D., Cámara, C., López‐Granados, E., Nozal, P., Molina, L. D. P., Bravo‐Gallego, L. Y., Paz‐Artal, E., Pion, M., Correa‐Rocha, R., Ortíz, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3844997 · Cited by 4

Cellular and Humoral Functional Responses After BNT162b2 SARS-CoV-2 mRNA Vaccination Differ Between Naïve and COVID-19-Recovered IndividualsPreprint

Lozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Alcamı́, J., García‐Pérez, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3882133 · Cited by 1

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals

Samanovic, M. I., Cornelius, A. R., Gray-Gaillard, S. L., Allen, J. R., Karmacharya, T., Wilson, J. P., Hyman, S., Tuen, M., Koralov, S. B., Mulligan, M. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8961 · Cited by 116

Cellular and Humoral Functional Responses After BNT162b2 SARS-CoV-2 mRNA Vaccination Differ Between Naïve and COVID-19-Recovered Individuals

Lozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamı́, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 50